Precision Neurogenetics for a New Era in Mental Health

Cognigenics is developing the first RNAi-based therapeutics for psychiatry—engineered for precise, reversible modulation of neural circuits.

Our lead candidate in development, COG-301, is a short-interfering RNA (siRNA) therapeutic, delivered via lipid conjugates and administered intranasally. COG-301 is designed to selectively downregulate 5-HT2a receptor expression in targeted brain regions implicated in the limbic hyperactivity associated with anxiety and psychosis in Parkinson's Disease Psychosis (PDP).

With intended weekly dosing, COG-301, based on promising preclinical results, aims to provide durable, non-sedating symptom relief while preserving cognitive function. The therapy is being developed for self-administration and cold storage at home, offering a potential alternative to current systemic treatments.

WHY IT MATTERS

Small-molecule drugs, a legacy technology developed over a century ago, rely on protein binding and often affect multiple receptor systems indiscriminately, leading to sedation, emotional blunting, and metabolic side effects. At Cognigenics, we are advancing a new era of neuropsychiatric treatment with RNA therapeutics that act upstream at the mRNA level, enabling precise, durable, and cell-specific modulation of neural targets. This approach results in fewer off-target effects, improved tolerability, and non-sedating, next-generation interventions.

THERAPEUTIC AND COMMERCIAL CASE RESULTS THAT SET A NEW STANDARD

In our previous preclinical models of anxiety and perceptual dysregulation, COG-201, an shRNA neuromodulator outperformed leading pharmaceutical benchmarks on both behavioral and electrophysiological endpoints. Our therapy demonstrated:

• Improved memory and anxiety outcomes
• Appears to be well tolerated with no observed off-target effects
• Regionally selective silencing of target genes

These results, validated by third-party laboratories, lay the foundation for a first-in-class RNAi therapeutic in psychiatry, backed by a delivery system that is scalable, targeted, and regulatory-track ready.

Developing Therapeutics with Speed and Precision

Cognigenics operates with a lean, translational model. It outsources manufacturing, safety, and toxicology to world-class CROs and CMOs while maintaining scientific leadership in target design, formulation, and delivery. This accelerates timelines and reduces burn without compromising rigor.

We're not just building drugs. We're building a platform for scalable, precision psychiatry in the Genetic Age.

RNA Therapeutics, Engineered for Precision Neuromodulation

At Cognigenics, we are building the next generation of psychiatric treatments by integrating molecular genetics, neuroscience, and targeted delivery technologies.

Our unique AcuGen platform centers on short interfering RNA (siRNA)—a highly selective therapeutic modality that allows us to modulate gene expression with unprecedented spatial and temporal precision. Delivered via lipid conjugates, our therapeutics reach the brain noninvasively through intranasal administration, bypassing the blood-brain barrier.

Target: 5-HT2a Receptor

Decades of pharmacological and imaging research have implicated 5-HT2a receptor overactivation in limbic and cortical circuits as a key mechanism underlying hallucinations and psychosis, particularly in Parkinson's Disease Psychosis. The clinical efficacy of selective 5-HT2a antagonists and evidence of upregulated receptor density in affected brain regions support this.

Our approach is a fundamental change. Instead of the outside-in approach of traditional small-molecule drugs, we're developing an inside-out approach, modulating only specific neuronal receptors in the brain.

COG-301 silences 5-HT2a gene expression at the mRNA level using siRNA, enabling receptor-specific downregulation without polypharmacology.

Precision Delivery via Intranasal Lipid Conjugates

Our patent-pending lipid conjugates formulation will enable nose-to-brain targeting—a direct path to the limbic and cortical regions implicated in psychiatric illness. Intranasally delivered, this formulation is designed to:

• Avoid systemic exposure
• Enable weekly dosing
• Require no implanted hardware or infusion devices
• Allow at-home patient administration and cold storage in a standard refrigerator

This approach balances efficacy, safety, and scalability in a way conventional psychiatric treatments cannot.

Advancing a New Class of CNS Therapeutics

We believe Cognigenics is defining a new category of neurotherapeutics:

Precise. Reversible. RNA-based.

COG-301, our lead candidate under development, embodies this innovation. It's a first-in-class RNAi therapy for anxiety and perceptual symptoms in PDP—and it lays the foundation for broader expansion across psychiatric and neurodegenerative indications.

Scientific, Strategic, and Operational Leadership in Precision Psychiatry

At Cognigenics, we bring together a cross-disciplinary team of scientists, clinicians, entrepreneurs, and technologists to advance the future of RNA therapeutics for neuropsychiatric disease. Our leadership spans neuroscience, genetic medicine, biotech commercialization, and venture strategy, all aligned around one goal: transforming brain health through precision genetic modulation.

Empowering Lives Through Precision Neurogenetics

At Cognigenics, we are advancing a new class of therapeutics that aims to redefine treatment outcomes for neuropsychiatric disorders. Our siRNA-based therapies, delivered via intranasal lipid conjugates, are designed to target the molecular drivers of psychiatric and cognitive symptoms, in order to offer safe, reversible modulation of brain circuits without systemic exposure.

MEASURABLE IMPACT, MEANINGFUL CHANGE

Improved Mental and Emotional Balance

By modulating activity in the interpeduncular–ventral hippocampus pathway, our therapeutics show promise in restoring emotional regulation, enhancing mood, and increasing stress resilience.

Our Goal: A Better Experience for Patients

Noninvasive, At-Home Administration

Our delivery system is designed for simplicity: a once-weekly, self-administered intranasal spray that may reduce the need for daily pills or clinical procedures.

Empowering Patient Control

Ease of use promotes adherence and places therapeutic management back in the hands of the individual.

A Foundation in Science, A Vision for Impact

Third-Party Validation

Our outcomes are validated through studies performed at independent, AAALAC-accredited laboratories utilizing behavioral assays, immunohistochemistry, qPCR, and electrophysiology, and confirmed through peer-reviewed evaluation.

A Platform for Broader Transformation

While we begin with Parkinson's Disease Psychosis with Anxiety, our AcuGen platform is scalable across cognitive impairment, neurodegeneration, and anxiety spectrum conditions.

Advancing siRNA Therapeutics for Neuropsychiatric Disease

Cognigenics is developing a platform of precision RNA therapeutics for neuropsychiatric and neurodegenerative conditions. Each candidate is built on our core technology: short interfering RNA (siRNA) delivered via intranasal lipid conjugates, enabling targeted receptor modulation in the brain without systemic exposure.

Our lead candidate, COG-301, exemplifies this strategy. It is currently being developed for Parkinson's Disease Psychosis with Anxiety, an area of high unmet medical need with limited therapeutic options.

Pipeline Overview

* Pipeline programs under preclinical investigation for future expansion. Subject to refinement as clinical data emerges.

Lead Candidate: COG-301

COG-301 is a weekly siRNA therapeutic targeting 5-HT2a, a receptor implicated in the limbic hyperactivity seen in Parkinson's Disease Psychosis. Our goals:

• Selective gene silencing without the side effects of systemic antipsychotics
• Durable symptom relief without sedation or tolerance
• Noninvasive, intranasal dosing suitable for at-home administration
• COG-301 is being developed under a neurology/psychiatry regulatory path, with plans for first-in-human trials following IND-enabling studies in 2025.

Platform Expansion

COG-301 leads our clinical path, and our siRNA + lipid conjugates platform is designed to be modular and scalable.

Programs address:

• Cognitive impairment in aging and early neurodegeneration
• Anxiety spectrum disorders across populations
• Genetic modulation of other serotonin, glutamate, or GABA receptor subtypes

Our pipeline reflects not only individual therapeutics but a broader strategy to redefine neuropsychiatry through gene-level control.

A New Investment Frontier in Genetic Psychiatry

Cognigenics offers investors access to a high-potential, de-risked therapeutic platform at the intersection of neuroscience, RNA therapeutics, and noninvasive delivery.

Market Rationale

• ~1 million patients with Parkinson's in the U.S.; 40–50% of advanced-stage patients develop psychosis or severe anxiety
• No targeted RNA-based therapies exist for psychiatric indications
• First-mover advantage in intranasal siRNA delivery targeting CNS receptors

Capital Use

Next-stage capital will fund:

• COG-301 NEW design and testing (in vitro and in vivo)
• Final GLP tox and dose-ranging studies
• IND submission and Phase I trial readiness
• Expanded IP filings and manufacturing scale-up

Join Us

We're building a new modality for psychiatry—and a platform for durable, precision CNS therapeutics.